RainDance Technologies Appoints Scott Bortner Vice President of Intellectual Property
News Jan 22, 2015
RainDance Technologies, Inc. has announced the appointment of Scott R. Bortner, Ph.D., J.D., as its new Vice President of Intellectual Property. Dr. Bortner will be responsible for strengthening and defending the IP portfolio underlying the company’s core digital droplet technology and applications for novel, non-invasive liquid biopsy research.
Dr. Bortner brings more than 25 years of experience leading teams to create, grow and protect some of the genomics industry’s largest IP portfolios, including patents, trade secrets, copyrights, and trademarks. During his career, he has held senior IP Counsel positions at leading law firms and life sciences companies including Applied Biosystems, Affymetrix and Natera.
As a senior attorney for Applied Biosystems, Dr. Bortner managed legal teams; filed patents; counseled management and scientists; performed extensive freedom to operate analyses and due diligence; drafted licenses; and managed litigation.
He also provided the patent due diligence for the $725 million acquisition of Ion Torrent in 2010. Dr. Bortner holds a Ph.D. in Microbiology and Molecular Genetics from Harvard University, a B.A. in Biochemistry from Cornell University, and a J.D. degree from Santa Clara University School of Law.
“Over the last decade, RainDance has developed and in-licensed a foundational IP portfolio with more than 180 patent applications worldwide for its core digital droplet technology and novel liquid biopsy applications,” said Dr. Bortner. “I’m honored to be part of a team that is transforming the way we analyze cell-based and cell-free biomarkers to advance genomics disease research.”
“At Applied Biosystems, Scott managed one the largest intellectual property patent positions for Next-Generation Sequencing (NGS) and PCR technologies in the genomics industry,” said Michael Hunkapiller, Ph.D., a Board Director at RainDance Technologies and former President and General Manager at Applied Biosystems. “Scott has been very successful developing and prosecuting patent portfolios and we will look to him to further capture value from RainDance’s innovative pursuits.”
Complex Genetics Made Simple
RainDance Technologies offers a full product portfolio to research cell-free and cell-based biomarkers for hereditary risk predisposition, initial detection, pathology, and residual disease. The company’s research-use products include:
• RainDrop® System: Ultra-sensitive digital PCR system for research of early detection and monitoring biomarkers for cancers, viruses, pathogens, and immune disorders.
• ThunderBolts™ Cancer Panel: Comprehensive Next-Generation Sequencing (NGS) panel enabling highly sensitive, rapid, low input and primary tumor profiling research in fresh biopsy, plasma and FFPE samples.
• ThunderStorm® System: High-throughput, fully automated NGS content enrichment solution enabling researchers to generate high-quality data on large-scale disease panels with a simple and affordable workflow.
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
No Country for Old GenesNews
Our modern world is radically different from the one we evolved in, and that creates a mismatch between the environment our genes were evolved to face, and the world those genes now encounter. A new review looks at how certain genes that benefited humans in our genetic past now predispose us to disease in old age.READ MORE
CRISPR Editing Stops HIV Virus in Infected CellsNews
Human immunodeficiency virus-1 (HIV-1) infection is a chronic disease affecting more than 35 million people worldwide. The infection can be controlled by antiretroviral therapy (ART), but there is still no complete cure. Now, a new study targeting the regulatory genes of the virus using CRISPR/Cas9 has helped block the production of the virus by infected cells.READ MORE